C-reactive protein to albumin ratio predict responses to programmed cell death-1 inhibitors in hepatocellular carcinoma patients

doi:10.4251/wjgo.v16.i1.61

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1637)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-7) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

774

Figures (1-7)

183

Tables (1-3)

160

Sum=1207

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

102

Download

264

Sum=366

Jan 15, 2024 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2024; 16(1): 61-78
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.61

Full Size Figure Download Figure

Figure 4 Calibration curves for nomogram models related to overall survival and progression-free survival. A: Calibration curves of overall survival at 12 mo, 18 mo and 24 mo; B: Calibration curves of progression-free survival at 9 mo, 12 mo and 15 mo. OS: Overall survival; PFS: Progression-free survival.

Citation: Li BB, Chen LJ, Lu SL, Lei B, Yu GL, Yu SP. C-reactive protein to albumin ratio predict responses to programmed cell death-1 inhibitors in hepatocellular carcinoma patients. World J Gastrointest Oncol 2024; 16(1): 61-78
URL: https://www.wjgnet.com/1948-5204/full/v16/i1/61.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i1.61